Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aerobic Exercise Training Increases Circulating sRAGE in Adults With Type 2 Diabetes: Associations With Sheddase Regulation.

Diabetes, obesity & metabolism·2026
Same author

Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date.

Frontiers in endocrinology·2026
Same author

Lamin A/C in health, laminopathies, and familial partial lipodystrophy 2.

Trends in endocrinology and metabolism: TEM·2026
Same author

EBF2 variant identified in a patient with atypical partial lipodystrophy causes adipose fibrosis and dysfunction.

The Journal of clinical investigation·2026
Same author

Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted <i>APOC3</i> antisense oligonucleotide.

American journal of preventive cardiology·2025
Same author

Altered lipid metabolism and inflammatory programs associate with adipocyte loss in familial partial lipodystrophy 2.

The Journal of clinical investigation·2025

Related Experiment Video

Updated: Jun 17, 2026

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

Rationale for leptin-replacement therapy for severe lipodystrophy.

Elif A Oral1, Jean L Chan

  • 1University of Michigan, Ann Arbor, Michigan, USA.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
|January 12, 2010
PubMed
Summary

Severe lipodystrophy is linked to leptin deficiency. Leptin replacement therapy (metreleptin) shows promise in improving metabolic dysfunction in patients with generalized lipodystrophy.

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Related Experiment Videos

Last Updated: Jun 17, 2026

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice
06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Genetics

Background:

  • Lipodystrophy syndromes involve loss of subcutaneous adipose tissue, leading to relative leptin deficiency.
  • Metabolic complications are a hallmark of severe lipodystrophy.
  • Leptin, an adipocyte-secreted hormone, plays a crucial role in metabolic regulation.

Purpose of the Study:

  • To evaluate the hypothesis that metabolic abnormalities in lipodystrophy stem from leptin deficiency.
  • To assess the potential of leptin replacement therapy as a treatment for generalized lipodystrophy.

Main Methods:

  • Comprehensive MEDLINE literature search (1998-2009) focusing on leptin and lipodystrophy.
  • Review of clinical experience and published nonrandomized, open-label trials.
  • Analysis of data from over 100 patients with severe lipodystrophy (excluding HIV-related cases).

Main Results:

  • Recombinant human methionyl leptin (metreleptin) therapy improved glycemic control and insulin sensitivity.
  • Treatment led to reductions in plasma triglycerides, liver volume, and lipid content.
  • Neuroendocrine and immunologic parameters also showed improvement with metreleptin.

Conclusions:

  • Treating severe lipodystrophy as a leptin deficiency syndrome is supported by evidence.
  • Leptin replacement therapy demonstrates potential for improving metabolic outcomes in affected patients.
  • Metreleptin is generally well-tolerated and available via expanded access for severe cases.